Clinical trials for Sarcoma and GIST

71 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 3 Sarcoma and GIST #NCT07218926 #2025-522229-37-00

Étude comparant l'IDRX-42 (GSK6042981) au sunitinib chez des participants atteints de tumeurs stromales gastro-intestinales après un traitement par imatinib.

GIST Locally Advanced Metastatic 1 Targeted therapy

Systemic Treatment-Naive

5 recruiting sites

GlaxoSmithKline

Phase 3 Sarcoma and GIST #NCT04307277 #2024-515384-62-00

[CHIC-STS01] Intérêt de la chimiothérapie périopératoire chez les patients atteints de sarcome des tissus mous localisé à haut risque selon la classification CINSARC

Soft tissue sarcoma Localized None Surgery Grade 1 Grade 2 Grade 3

19 recruiting sites

Institut Claudius Regaud

Phase 3 Sarcoma and GIST #NCT04031677

[STRASS2] Chirurgie avec ou sans chimiothérapie néoadjuvante dans le sarcome rétropéritonéal à haut risque

Soft tissue sarcoma Localized None Systemic Treatment-Naive

Surgery

3 recruiting sites

EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer

Phase 3 Sarcoma and GIST #NCT04757337 #2018-000542-20

[GERICO14] Comparaison du cyclophosphamide oral et de la doxorubicine chez les patients âgés de 65 ans et plus atteints d'un sarcome des tissus mous avancé ou métastatique

Soft tissue sarcoma Locally Advanced Metastatic None Systemic Treatment-Naive

1 recruiting site

UNICANCER

Phase 3 Sarcoma and GIST #NCT03805022 #2018-000186-36

[CIRSARC] Bénéfice d'une chimiothérapie périopératoire intensifiée chez les patients CINSARC à haut risque atteints de sarcomes des tissus mous résécables

Soft tissue sarcoma Localized None Systemic Treatment-Naive

6 recruiting sites

Institut Bergonié

Phase 3 Sarcoma and GIST #NCT06127407 #2023-508507-20-00

[CHONQUER] Ivosidénib chez les participants atteints d'un chondrosarcome conventionnel localement avancé ou métastatique non traité ou ayant déjà reçu un traitement systémique

Bone sarcoma Chondrosarcoma Locally Advanced Metastatic None 1 Systemic Treatment-Naive Chemotherapy Targeted therapy

8 recruiting sites

Phase 3 Sarcoma and GIST #NCT04650984 #2024-512789-32-00

[FIBROSARC] Une étude comparant l'efficacité de L19TNF+Doxorubicine à celle de la doxorubicine seule en traitement de première ligne chez les patients atteints d'un sarcome des tissus mous avancé ou métastatique

Soft tissue sarcoma Locally Advanced Metastatic None Systemic Treatment-Naive

Chemotherapy

4 recruiting sites

Philogène SpA

Phase 3 Lung cancer Colon cancer Rectal cancer Pancreas cancer Sarcoma and GIST #NCT06332274 #2023-503316-33-00

[UMBRELLA] TISLELIZUMAB chez les patients atteints de cancer avec maladie résiduelle moléculaire

NSCLC (Non-Small Cell Lung Cancer) Soft tissue sarcoma Localized Locally Advanced None Surgery Chemotherapy Surgery Chemotherapy

EGFR Immunotherapy Immunotherapy

4 recruiting sites

Gustave Roussy, Campus du cancer, Grand Paris

Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer #NCT03175224 #2024-514542-37-00

[SPARTA] APL-101 chez des patients atteints de tumeurs solides avancées avec anomalies de MET - Cohortes C, D et F

Locally Advanced Metastatic MET 1 2 3 or more

BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ALK ROS-1 Systemic Treatment-Naive Targeted therapy

5 recruiting sites

Apollomics

Phase 2 Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Sarcoma and GIST Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00

[Pan-MSI-ACSE] DOSTARLIMAB pour le cancer localement avancé ou métastatique (non colorectal/non endométrial) avec tumeur dMMR/MSI

Stomach Oesogastric junction Soft tissue sarcoma Adenocarcinoma Ampullary carcinoma Locally Advanced Metastatic MSI/dMMR None Systemic Treatment-Naive CPS Negative (< 1) CPS Positive (1 <= X < 5)

Immunotherapy Radiotherapy

6 recruiting sites

UNICANCER